A215600 Share Price Performance
₩0
-3285.00 (-100.00%)
Price ₩0
Share Pricen/a
SillaJen, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
A215600 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
SillaJen, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -174.16
- 63.95%
- -220.98%
- 0.7%
About A215600
- Founded
- 2006
- Employees
- 57
- CEO
- WebsiteView website
SillaJen, Inc. engages in developing technologies and products using genetic engineering in South Korea. The company develops Pexa-Vec, which is in phase 2 clinical trial to treat renal Cell Carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. It also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-600 Series and JX-970 to treat solid tumors and is in preclinical trial. SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea.
